Boehringer opts to take up rights to Oxford BioThera's oncology target

Privately-held, UK-based Oxford BioTherapeutics says that German family-owned pharma major Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration.

The target was discovered using Oxford BioTherapeutics’ proprietary OGAP system, which incorporates one of the world’s largest proprietary proteomic databases, integrating clinical, experimental and expression data.

This represents the first option exercised under the companies’ oncology target discovery and validation collaboration established in 2013. Under the terms of the deal, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target. Oxford BioTherapeutics will receive undisclosed development and regulatory milestone payments, and royalties on any future product sales.